Indometacin farnesil
Appearance
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | To indometacin |
Elimination half-life | 1.5 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.242.585 |
Chemical and physical data | |
Formula | C34H40ClNO4 |
Molar mass | 562.15 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Indometacin farnesil (INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon, respectively.
External links
- Infree (indometacin farnesil capsules) Full Prescribing Information Archived 2010-12-03 at the Wayback Machine from Eisai Co.